Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?
Although not immediately practice-changing, impressive results from the NICHE-2 trial may open a way to a ‘watch and wait’ approach for some patients
The role of neoadjuvant versus adjuvant immunotherapy is no simple comparison but instead involves a complex interplay of factors, based on tumour immune responsiveness, immunotherapy type, combination partners and trial design
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.